BRAF and Alzheimer disease: Several guidelines recommend the exploration of the treatment landscape for advanced rectal and anal AD.3,40 Biomarker information such as RAS/BRAF V600E mutation, ERBB2 amplification, MSI, and TMB is the foundation for determining the appropriate molecular-targeted drugs.